Efficacy and safety of infliximab in the treatment of ulcerative colitis in children
Objective To evaluate the efficacy and safety of infliximab(IFX)in children with ulcerative colitis(UC).Methods The clinical data of 21 children with ulcerative colitis who received IFX at Jinan Children's Hospital from January 2018 to December 2022 were analyzed retrospectively.The pediatric ulcerative colitis activity index(PUCAI),ulcerative colitis endoscopic index of severity and laboratory findings were compared to assess the efficacy and safety of IFX.Results There were 12 males and 9 females among 21 children with UC.IFX efficacy analysis showed that the clinical response rate at week 14 was 76.2%(16/21)and the clinical response rate was 66.7%(14/21).The clinical response rate in maintained remission at week 30 was 76.4%(13/17)and the sustained response rate was 58.5%(10/17).PUCAI score,C reactive protein,erythrocyte sedimentation rate and fecal calprotectin were significantly decreased in 14 and 30 weeks of IFX treatment compared with before treatment(P<0.05),and hemoglobin and albumin were significantly improved(P<0.05).At 14 weeks,8 cases achieved mucosal healing,6 cases reduced severe mucosal inflammation to moderate inflammation,4 cases reduced moderate inflammation to mild inflammation,and 2 cases showed no improvement in mucosal inflammation.The incidence of IFX infusion reactions was 43%(9/21),including acute infusion reactions,delayed infusion reactions,and transaminase elevation.Infections were the most common during treatment,with an incidence of 38%(8/21).Conclusion IFX is effective on UC in children,However,we should be alert to the occurrence of adverse events during the treatment.
国家科技期刊平台
NSTL
万方数据
